MD Anderson and Affimed Announce Clinical Immuno-Oncology Development Collaboration
Wednesday, January 4, 2017 - 05:01
in Health & Medicine
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed's TandAb technology in combination with MD Anderson's natural killer cell (NK) product.